Staar Surgical Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and thank you for joining us for Canaccord Genuity's 2026 MedTech, Diagnostics, Digital Health, and Services Forum. My name is John Young, and I am one of the analysts here. I am very pleased to be joined today by the management team of STAAR Surgical. We have Warren Foust, President and CEO, and Deborah Andrews, EVP and Chief Financial Officer. For those less familiar with the story, STAAR is a commercial stage company focused on implantable lenses for vision correction. Its product, the EVO ICL, is a lens made from a proprietary biocompatible material called Collamer that is placed in the eye to correct nearsightedness without removing the corneal tissue the way LASIK does. As someone who has the product in their eyes, I can tell you this performance is remarkable. Warren, thanks for joining us today.
You were named permanent CEO in August after serving as interim co-CEO since February. With a few months in the permanent seat, how would you characterize where STAAR stands today, and what are your top priorities for the next 12 months?
Yeah. Thanks, John. Thanks for having us, first of all, and thanks for being patient. That is amazing. Look, we are really excited at STAAR. We have had a good start to the year. Deborah and I had the chance to lead the organization together for the first half of the year, and we established three priorities at that time: revenue growth, returning ourselves to growth, which we had been previously and we had lost track of, candidly, returning to profitability, which is an important metric, and then also establishing an innovation pipeline. For far too long, I think the company was sort of sitting in a takeout position, and you saw us go through a couple of years of disruption.
One everyone was aware of while we were in the potential transaction with Alcon, and a year prior to that when that was happening behind the scenes, and the company lost a little bit of focus, and now we are really clearly focused on innovation. Now that we have strong revenue growth, and you just saw the third quarter results, 31% in China on an adjusted basis, which we are really proud of. That is our largest market. Unlike most U.S. publicly traded companies, half the business in China, that has been for many years a shining star for us, and it was one that in almost all periods has grown up until the 2023, 2024 timeframe. We feel like we have rectified that. That is important. That is one of the priorities for us.
Now as we look at going first in human with a couple of new lenses that we're excited about, we will do that over the course of the next couple months. That will set us on a pace for the innovation that is to come. Those three things I think we are most excited about.
Got it. Then another change too is much of the leadership changes you have made since becoming permanent CEO. You brought in a new Chief Technology Officer, a new Head of BD, a new VP of Asia Pacific, and you are bringing back the former CEO, David Bailey, as Chief Commercial Officer. What gaps are you filling, and what specifically do you want David to do on the commercial side as well?
Yeah, great question. We feel like we have a good squad. We have folks that have worked with Deborah in the past. Deborah came back to join us, if you remember, in 2025 to reestablish that profitability and return to revenue growth, and has done such a great job in leading us to do that. Now we are bringing back David Bailey, who was a former CEO here, and in the commercial organization, we have a real opportunity to drive execution in a more standardized way, to really ensure that we are incentivizing our field teams relative to our actual goals and objectives. I think that is really important. But also to look at where it makes sense for us to be direct, where it makes sense for us to be indirect, look at margins across the entire organization, continue to help with the great cost-cutting measures that we have made.
We do not believe we can cut our way to profitability. We actually grow our way, and I think we are demonstrating that. But every amount of growth that we enjoy, we should take some leverage on the cost side, and we intend to do that, and David can help us there. I would also mention, you mentioned the new Chief Technology Officer, Ben Park. Ben led emerging technology at Align Technology for eight years. That is the Invisalign technology for the orthodontics in the room. We are really excited about what he is going to bring.
We've had many projects working in the background for years, but in some ways, they've been more almost academic from the standpoint of it's smart people working on really important things, but they've not been organized in a cadence that we believe that we can start to make investments against, be good at capital allocation, and then start to bring that forward in a true portfolio.
We're excited about that. Maybe we could jump to everyone's favorite topic, which is always China.
Yeah. The revenue grew 31% against the adjusted prior year base, and all that growth came from higher average selling prices on the shift to EVO+ and toric lenses, and you're also in a backlog state during Q3.
How are you just thinking about the opportunity for this continued EVO+ adoption in China, and maybe you could provide where in the mix it is today exiting the quarter?
Thanks. We've been really pleased with EVO+. They call it V5 locally, so V5 we'll refer to it as. When we started the year, we began the launch. We actually put a few units out at the end of 2025, but think of the launch as January of 2026. We put a few units out. We intended to move our production to Switzerland so that we can be tariff-free as we take product from Switzerland to China, and we had a certain number of EVO+ units that we expected to sell, and candidly, the demand outstripped that pretty substantially and pretty fast. We had to change our demand plan for the Swiss plant as we were scaling the plant up to build either V4 or V5. So we had some complexity in the supply chain, and that hit us a little bit in Q3.
As you said, our growth came from mix, average selling price because of mix, both toric and our V5. As a result, we were not able to even ship enough V5 to the market. We were a little light on units compared to what I think we could have been, so we could have had potentially even a little bit stronger quarter. As far as the mix of it, what we said was at the end of Q2, we exited around 30%. We stopped giving that number because our hospitals, which compete with each other, they have asked us to stop providing that. I can tell you that the mix of V5 has grown. I can tell you that the mix of toric. Does everyone know what a toric is? When you have a spherical lens, your eye is designed to be shaped like a basketball.
Half of us, probably, it starts to get shaped a little bit like a football. That changes the steep axis of your eye, and yours might be slightly different than mine and yours. We make a custom lens. For every patient that needs that custom lens, all the way to 360 degrees of axis, we will make that lens. It is a competitive moat for us in a lot of ways, because we stock in the normal histogram most of those units, and then anything that falls outside of that, we make it as a truly custom lens. That complexity of our supply chain creates a little bit of added issue when you think about this V5 launch and scale. I think that is important, even as we think about competitors that come, because it is hard for them to do that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
